Serum IgA, IgM, and IgG responses in COVID-19

Ma, Huan; Zeng, Weihong; He, Hongliang; Zhao, Dan; Dehua, Jiang; Zhou, Peigen; Cheng, Linzhao; Li, Yajuan; Ma, Xiaoling; Jin, Tengchuan

doi:10.1038/s41423-020-0474-z

Cited by 429 publications

(526 citation statements)

References 7 publications

Supporting

Mentioning

456

Contrasting

Unclassified

Order By: Relevance

“…Serum IgA antibody responses may be detectable earlier than IgG and IgM responses1617 and can persist for at least 38 days in hospital patients recovering from covid-19 18. This is consistent with a recent Cochrane review, which found that IgA based serological testing had greater sensitivity than other methods 5.…”

Section: Look For Igasupporting

confidence: 85%

Are we underestimating seroprevalence of SARS-CoV-2?

Burgess

Ponsford

2020

BMJ

View full text Add to dashboard Cite

show abstract

Section: Look For Igasupporting

confidence: 85%

Are we underestimating seroprevalence of SARS-CoV-2?

Burgess

Ponsford

2020

BMJ

View full text Add to dashboard Cite

show abstract

“…Profiling of early humoral response in one study of patients with COVID-19 determined that IgA and IgM antibodies can be detected as early as 5 days after new infection, with higher levels detected in the second and third weeks. 51,52 Other studies detected optimal IgM antibodies toward the end of the first week that peaked during the third week after symptom onset, and may correspond to the emergence of negative results by RT-PCR tests as the viral load is cleared (Figure 2). 16,19,51,53 Another report determined earlier IgA seroconversion than IgM 54 or that IgA is detected at higher levels than IgM.…”

Section: Serology Testingmentioning

confidence: 94%

“…55 IgG antibodies become detectable later in the infection course around 7-14 days after symptom onset and levels remained relatively high until 6 weeks. 51,52 Although the data remain premature, a small study of 285 patients with COVID-19 reported that 100% of patients tested positive for IgG within 20 days after symptom onset. Seroconversion for IgG and IgM occurred simultaneously or sequentially between the third and fourth weeks, and both levels plateaued within 6 days after seroconversion.…”

Section: Serology Testingmentioning

confidence: 99%

COVID‐19 Clinical Diagnostics and Testing Technology

2020

View full text Add to dashboard Cite

Given the global nature of the coronavirus disease 2019 (COVID‐19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for detecting the novel coronavirus. We describe the current clinical diagnostics and technology, including molecular and serological testing approaches, for severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) testing as well as address their advantages and limitations. Nucleic acid amplification technology for molecular diagnostics remains the gold standard for virus detection. We highlight alternative molecular detection techniques used for developing novel COVID‐19 diagnostics on the horizon. Antibody response against SARS‐CoV‐2 remains poorly understood and proper validation of serology tests is necessary to demonstrate their accuracy and clinical utility. In order to bring the pandemic under control, we must speed up the development of rapid and widespread testing through improvements in clinical diagnostics and testing technology as well as access to these tools.

show abstract

“…Consistent with the fact that SARS CoV-2 initially infects in the nasopharynx, IgA antibodies that bind to SARS-CoV-2 are produced rapidly after infection and remain elevated in the plasma for at least 40 days after the onset of symptoms (20)(21)(22)(23). IgA antibodies bind to the RBD and can neutralize SARS-CoV-2 (20)(21)(22). However, the precise contribution and molecular nature of the IgA response to SARS-CoV-2 has not been reported to date.…”

Section: Introductionmentioning

confidence: 99%

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

Wang

Lorenzi

Muecksch

et al. 2020

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 primarily infects cells at mucosal surfaces. Serum neutralizing antibody responses are variable and generally low in individuals that suffer mild forms of the illness. Although potent IgG antibodies can neutralize the virus, less is known about secretory antibodies such as IgA that might impact the initial viral spread and transmissibility from the mucosa. Here we characterize the IgA response to SARS-CoV-2 in a cohort of 149 individuals. IgA responses in plasma generally correlate with IgG responses and clones of IgM, IgG and IgA producing B cells that are derived from common progenitors are evident. Plasma IgA monomers are 2-fold less potent than IgG equivalents. However, IgA dimers, the primary form in the nasopharynx, are on average 15 times more potent than IgA monomers. Thus, secretory IgA responses may be particularly valuable for protection against SARS-CoV-2 and for vaccine efficacy.

show abstract

Serum IgA, IgM, and IgG responses in COVID-19

Cited by 429 publications

References 7 publications

Are we underestimating seroprevalence of SARS-CoV-2?

Are we underestimating seroprevalence of SARS-CoV-2?

COVID‐19 Clinical Diagnostics and Testing Technology

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

Contact Info

Product

Resources

About